ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- A transferrin receptor-targeted liposome for iron metabolism regulation-augmented photodynamic therapy in glioblastoma.Bioactive materials · 2027Article
- Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells.Bioengineering & translational medicine · 2026Article
- Framework Nucleic Acids as a Nanocontainer for Delivering Heterogeneous Molecular Drugs.Pharmaceutics · 2026Review
- Intranasal Delivery of Curcumin-Loaded Pure Drug Self-Assembled Lipid-Based Nanoparticles for Targeted Therapy of Depression.International journal of nanomedicine · 2026Article
- Photodynamic therapy simultaneously induces ferroptosis- and apoptosis-like lipid signatures in ovarian cancer cells.Cell death & disease · 2025Article
- Theranostic Verteporfin-Conjugated Upconversion Nanoparticles for Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Article
- Impact of oil phase composition on the efficacy of nanoemulsions for verteporfin-mediated photodynamic therapy in ovarian cancer.Nanoscale advances · 2025Article
- The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC).Cancer cell international · 2025Review
- Recent advances in phototherapy-based nanomedicine of lymphoma.Materials today. Bio · 2025Review
- Ultrasound-Enhanced Tumor Penetration of Carrier-Free Nanodrugs for High-Efficiency Chemo-Photodynamic Therapy of Breast Cancer.Journal of functional biomaterials · 2025Article
- Nanoparticles for Glioblastoma Treatment.Pharmaceutics · 2025Review
- Evaluation of Verteporfin as a Photosensitizer With Anticancer Activity Via System Biology Tools.Journal of lasers in medical sciences · 2025Article
- Carbon Dot-Based Nanoparticles: A Promising Therapeutic Approach for Glioblastoma.International journal of nanomedicine · 2025Review
- Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma.Advanced nanobiomed research · 2024Article
- Carrier-Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Nanoengineered photosensitizers for photodynamic priming to overcome P-glycoprotein-mediated multidrug resistance.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
Glioblastoma (GBM) is hard to treat due to cellular invasion into functioning brain tissues, limited drug delivery, and evolved treatment resistance. Recurrence is nearly universal even after surgery, chemotherapy, and radiation. Photodynamic therapy (PDT) involves photosensitizer administration followed by light activation to generate reactive oxygen species at tumor sites, thereby killing cells or inducing biological changes. PDT can ablate unresectable GBM and sensitize tumors to chemotherapy. Verteporfin (VP) is a promising photosensitizer that relies on liposomal carriers for clinical use. While lipids increase VP's solubility, they also reduce intracellular photosensitizer accumulation. Here, a pure-drug nanoformulation of VP, termed "NanoVP", eliminating the need for lipids, excipients, or stabilizers is reported. NanoVP has a tunable size (65-150 nm) and 1500-fold higher photosensitizer loading capacity than liposomal VP. NanoVP shows a 2-fold increase in photosensitizer uptake and superior PDT efficacy in GBM cells compared to liposomal VP. In mouse models, NanoVP-PDT improved tumor control and extended animal survival, outperforming liposomal VP and 5-aminolevulinic acid (5-ALA). Moreover, low-dose NanoVP-PDT can safely open the blood-brain barrier, increasing drug accumulation in rat brains by 5.5-fold compared to 5-ALA. NanoVP is a new photosensitizer formulation that has the potential to facilitate PDT for the treatment of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.